The University of Southampton
University of Southampton Institutional Repository

Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia
PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.
1471-4892
444-451
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Ward, Stephen G.
055fb146-f745-4b52-abf5-10d9de7e1673
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Ward, Stephen G.
055fb146-f745-4b52-abf5-10d9de7e1673

Blunt, Matthew D. and Ward, Stephen G. (2012) Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia. Current Opinion in Pharmacology, 12 (4), 444-451. (doi:10.1016/j.coph.2012.02.015). (PMID:22483603)

Record type: Article

Abstract

PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.

Full text not available from this repository.

More information

e-pub ahead of print date: 4 April 2012
Published date: August 2012
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 392721
URI: https://eprints.soton.ac.uk/id/eprint/392721
ISSN: 1471-4892
PURE UUID: 6aa7416f-9add-45c5-bc8b-256427511f55

Catalogue record

Date deposited: 14 Apr 2016 14:35
Last modified: 17 Jul 2017 19:14

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×